No-Deal Brexit Means ‘Re-Planning A Whole Industry,’ Says ABPI Chief
Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.
You may also be interested in...
Building more cold chain warehouses, finding alternative sources of medicine supplies, and halting parallel exports to mitigate product shortages. Just some of the ideas for tackling the consequences of a no-deal Brexit scenario put forward by industry representatives at a recent parliamentary committee hearing.
The BioIndustry Association is planning to contribute to a UK parliamentary inquiry into the likely effects of a “no-deal” Brexit on healthcare and medicines supply, and has urged companies to notify the government of the state of their contingency plans.
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.